All In Biotech

Drug Trial Radar · NCT01208389

Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 2010

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a follow-on to a Phase 1 dose-escalation and safety study.

Conditions

  • Leber Congenital Amaurosis

Interventions

  • voretigene neparvovec-rzylBiological

    One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events as a measure of safety and tolerabilityTime frame: 15 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.